Can p-tau217 go back to normal?

This is an active area of research. Early data from Alzheimer's disease-modifying treatment trials (lecanemab, donanemab) suggest that successful amyloid removal is associated with reductions in p-tau217 levels, though the magnitude of change and its clinical meaning are still being characterized. A single p-tau217 result should not be interpreted in isolation — trends over time and treatment context matter. Whether a decline in p-tau217 on treatment translates to meaningful cognitive benefit remains under active investigation. Do not interpret a declining p-tau217 value as confirmation that a treatment is working without clinical guidance.

What is a normal p-tau217 range?

Reference ranges are assay-specific and not interchangeable between platforms. On the most widely used clinical platform (Lumipulse/Fujirebio), published validation studies and clinical use at Mayo Clinic classify results as: negative (≤ ~0.18–0.20 pg/mL), indeterminate (~0.18–0.32 pg/mL), or positive (≥ ~0.32–0.33 pg/mL). Always use the reference range printed on your own lab report, which will show the cutoffs for the specific assay used.

What does it mean if my p-tau217 is in the gray zone?

A gray zone or indeterminate p-tau217 result falls between the negative and positive cutoffs. Roughly 15–30% of tested patients fall in this range. It reflects genuine uncertainty and typically prompts further evaluation — either repeat testing after symptom progression, additional biomarkers (Aβ42, NfL), or amyloid PET imaging. An indeterminate result is not a "positive" result.

Is the p-tau217 test the same as an Alzheimer's diagnosis?

No. P-tau217 is a diagnostic aid, not a diagnosis. A positive result increases the likelihood that Alzheimer's-related brain changes are present, but diagnosis requires integration of the result with clinical symptoms, cognitive testing, history, and often confirmatory testing. A negative result makes Alzheimer's less likely but does not completely exclude it.

What is the difference between p-tau217 and p-tau181?

Both are phosphorylated forms of the tau protein used as Alzheimer's biomarkers, but p-tau217 generally shows higher diagnostic accuracy in published studies. P-tau217 rises earlier and more steeply in Alzheimer's disease and correlates more strongly with amyloid PET results. Many specialty clinics now prefer p-tau217 when it is available.

Do I still need a PET scan or lumbar puncture after a p-tau217 result?

Sometimes. P-tau217 can rule in or rule out Alzheimer's-type pathology for most patients with confidence, potentially avoiding PET or lumbar puncture. However, confirmatory testing may still be recommended when results are borderline (gray zone), when the clinical picture is atypical, or when confirmation would directly change treatment decisions — particularly for Alzheimer's disease-modifying therapies that require confirmed amyloid pathology.

Why does my number look different from ranges I find online?

Different assay platforms produce different absolute numbers for the same patient. Lumipulse reports in pg/mL (typically 0.05–0.50+ range); AD-Detect (C2N) reports as a percentage (%p-tau217) in a different numeric range; ALZpath Simoa uses yet another scale. Never apply cutoffs from one platform to results from another. The reference range on your own report is the only valid interpretation guide.

What if my p-tau217 is intermediate but my amyloid PET scan is positive?

An intermediate p-tau217 result does not rule out Alzheimer's-related pathology. Blood biomarkers are screening and triage tools, while amyloid PET imaging directly measures amyloid deposition in the brain. A positive amyloid PET scan generally carries greater diagnostic weight than an intermediate blood biomarker result. It is possible to have an intermediate p-tau217 result while already demonstrating amyloid pathology on PET imaging, particularly in early disease stages.

Can kidney disease affect p-tau217 results?

Reduced kidney function may increase circulating p-tau217 levels and should be considered when interpreting results. Clinicians generally evaluate p-tau217 alongside kidney function markers such as creatinine, cystatin C, and eGFR.

P-tau217 Blood Test: Normal Range, Results Explained, and What High Levels Mean

Plasma

Other names: P-tau217, Phospho-tau 217, Phosphorylated Tau 217, p-tau 217, Plasma p-tau217, P-Tau217 Blood Test, ptau217, ptau 217, p tau217, p tau 217, P-Tau217 Normal Range, P-Tau217 Blood Test Results, Phospho-Tau 217 Plasma, Tau Protein Phosphorylated 217, AD-Detect p-tau217, AD-Detect ptau217 Plasma, Lumipulse p-tau217, ALZpath p-tau217, P-tau217/Aβ42 Ratio, Phospho-tau217, Tau 217, P-tau217 Alzheimer's Test, P-tau217 High, P-tau217 Levels, P-tau217 Range, P-tau217 Results, Fosfotau 217 (Spanish), Plasma Tau 217

Optimal Result: 0 - 0.18 pg/mL.

Brain Health

From Healthmatters.io Team and reviewed by HM Editorial Team

Written on June 1, 2026 | Last updated Updated on June 1, 2026

Lab Results Explained and Tracked

QUICK ANSWER

P-tau217 (phosphorylated tau at threonine 217) is a blood plasma biomarker that reflects Alzheimer's disease-related brain changes — specifically the presence of amyloid plaques and tau pathology — before or alongside symptoms.

Reference ranges vary by assay and lab. The most widely used clinical platform is Lumipulse (Fujirebio), for which Mayo Clinic and published validation studies use these approximate thresholds:

Result	Lumipulse p-tau217 (pg/mL)	Interpretation
Negative	≤ 0.18–0.20	AD-type pathology unlikely at this time
Indeterminate / Gray zone	0.18–0.32	Borderline — confirmatory testing or repeat may be needed
Positive	≥ 0.32–0.33	AD-type amyloid/tau pathology likely

Always use the reference range and cutoffs printed on your own lab report. Different assay platforms (Lumipulse, ALZpath, C2N AD-Detect, mass spectrometry-based) use different cutoff values that are not interchangeable.

If you have a specific Lumipulse result — what it typically means:

Example result (pg/mL)	Typical interpretation on Lumipulse
0.10–0.12	Clearly negative — AD-type pathology unlikely
0.18	Near the negative threshold — typically negative
0.22–0.25	Indeterminate / gray zone — further evaluation often recommended
0.30–0.32	Near the positive threshold — borderline; clinician judgment required
0.40+	Clearly positive — AD-type pathology likely

These values apply to the Lumipulse platform only and cannot be compared to results from AD-Detect, ALZpath, or other assays.

Key takeaway: A positive p-tau217 result increases the likelihood of Alzheimer's-type pathology — it does not confirm an Alzheimer's disease diagnosis. Interpretation requires the clinical picture, cognitive testing, and often confirmatory testing.

WHAT IS P-TAU217?

Tau is a protein that stabilizes structures inside neurons. In Alzheimer's disease, tau becomes abnormally phosphorylated at specific sites — including threonine 217 — and forms toxic tangles inside brain cells. Phosphorylated tau-217 (p-tau217) leaks into the bloodstream as this process occurs, making it detectable by a blood test.

Why p-tau217 specifically?

P-tau217 rises earlier and more steeply in Alzheimer's disease than other phospho-tau variants (p-tau181, p-tau231)
It reflects both amyloid plaque formation and tau tangle pathology simultaneously
Its plasma levels correlate strongly with amyloid PET and CSF biomarker results
In head-to-head comparisons, p-tau217 generally shows higher diagnostic accuracy than p-tau181 for identifying AD-type pathology

FDA clearance: The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio assay received FDA 510(k) clearance on May 16, 2025 — the first FDA-cleared blood-based diagnostic test to aid in identifying amyloid pathology associated with Alzheimer's disease. Labcorp launched nationwide availability of the test in August 2025. This marked a major shift from primarily research and specialty-center use toward broad clinical availability in the US.

WHAT DOES A HIGH P-TAU217 MEAN?

A high p-tau217 (above the positive cutoff for your assay) means Alzheimer's-type amyloid and tau pathology is likely present in the brain. The higher the value above the positive threshold, the stronger the signal.

What this means clinically:

The brain changes associated with Alzheimer's disease are likely occurring
It supports — but does not confirm — a clinical diagnosis of Alzheimer's disease
Your clinician may recommend confirmatory testing (amyloid PET scan or CSF biomarkers) if the result would change management
It may support eligibility for Alzheimer's disease-modifying treatments (lecanemab, donanemab) which require confirmed amyloid pathology

What a high result does not mean:

It does not mean you will definitely develop Alzheimer's dementia
It does not measure the rate of progression
It is not a standalone diagnosis — clinical symptoms and cognitive testing are always required

WHAT DOES A LOW P-TAU217 MEAN?

A low p-tau217 (below the negative cutoff for your assay) makes Alzheimer's-type amyloid and tau pathology unlikely at this time. It is a reassuring result in a patient being evaluated for possible Alzheimer's disease.

What this means clinically:

AD-type pathology is less likely as the explanation for current cognitive symptoms
It may redirect evaluation toward other causes of cognitive change (vascular dementia, Lewy body dementia, depression, metabolic causes)
It does not completely exclude early or preclinical Alzheimer's disease

A negative result, like all biomarker tests, is most meaningful when combined with clinical assessment and cognitive testing.

WHAT DOES AN INDETERMINATE / GRAY ZONE RESULT MEAN?

Many labs report p-tau217 using a two-cutoff approach — a lower negative threshold and a higher positive threshold — with a gray zone in between. This is intentional.

Why two cutoffs? The two-cutoff strategy improves overall diagnostic accuracy by reserving the highest-confidence "positive" and "negative" calls for results clearly outside the ambiguous middle range. Studies show that roughly 70–85% of patients can be classified with high confidence (negative or positive) using this approach, while 15–30% fall in the intermediate zone.

What to do with an indeterminate result:

Your clinician will weigh the result alongside cognitive testing, symptoms, and other biomarkers (Aβ42, p-tau217/Aβ42 ratio, NfL)
Repeat testing after 6–12 months may be recommended if symptoms progress
Amyloid PET or CSF biomarkers may be ordered for definitive classification
An indeterminate result is not a "bad" result — it reflects honest uncertainty rather than failure of the test

WHY DO REFERENCE RANGES DIFFER BY ASSAY?

The same patient's blood measured on different p-tau217 platforms will produce different absolute numbers. This is because each assay uses different antibodies, detection methods, and calibrators.

The major commercial platforms and their characteristics:

Platform	Manufacturer	Method	Common clinical use
Lumipulse	Fujirebio	Chemiluminescent immunoassay (CLEIA)	FDA-cleared; widely used in US hospital labs
ALZpath Simoa	ALZpath	Single molecule array (Simoa)	High sensitivity; used in research and specialty clinics
AD-Detect	C2N Diagnostics	Mass spectrometry (%p-tau217)	Reports as percentage, not absolute pg/mL
PrecivityAD2	C2N Diagnostics	Mass spectrometry + algorithm	Combines %p-tau217 with Aβ42/40 ratio

This is why the ranges differ: An "indeterminate" result on Lumipulse may correspond to a different absolute number than an "indeterminate" on ALZpath. Do not attempt to apply one platform's cutoffs to another platform's results.

P-TAU217 AND THE P-TAU217/Aβ42 RATIO

Some labs report the p-tau217/Aβ42 ratio alongside or instead of p-tau217 alone. Adding Aβ42 improves discrimination because:

Aβ42 falls as amyloid plaques accumulate (it gets "trapped" in the brain)
P-tau217 rises as pathology advances
The ratio therefore moves in a direction more powerfully than either marker alone

The Lumipulse FDA-cleared assay specifically measures the p-tau217/Aβ42 ratio. A high ratio (elevated p-tau217 combined with low Aβ42) strengthens the indication of AD pathology beyond p-tau217 alone.

CAN P-TAU217 BE ELEVATED BEFORE SYMPTOMS APPEAR?

Yes. P-tau217 can become abnormal years — potentially a decade or more — before dementia develops. This is one of the most clinically important features of the biomarker.

Alzheimer's disease pathology (amyloid plaques and tau tangles) begins accumulating in the brain well before memory loss or cognitive symptoms become apparent. P-tau217 reflects this underlying biological process, not the severity of current memory loss. This means:

A person with elevated p-tau217 may currently have mild cognitive impairment (MCI), subjective memory concerns, or even no obvious symptoms at the time of testing
An elevated result in a person without symptoms does not mean dementia is imminent — it indicates the biological process is underway
Early detection is the point: identifying Alzheimer's-type pathology before significant neuronal loss has occurred is precisely when disease-modifying treatments may have the greatest potential benefit

What presymptomatic elevation does not mean:

It does not predict with certainty that dementia will develop — not all people with amyloid pathology progress to symptomatic disease
It does not indicate how quickly symptoms will appear
It does not mean that immediate treatment is required in all cases — decisions about intervention depend on the full clinical picture

WHEN IS THE P-TAU217 TEST ORDERED?

P-tau217 is typically ordered in adults with:

New or progressive memory and thinking changes under evaluation for possible Alzheimer's disease
Mild cognitive impairment (MCI) where clarifying the underlying cause would change management
Atypical presentations where Alzheimer's vs. another dementia is unclear
Pre-treatment workup for patients being considered for amyloid-targeting therapies (lecanemab, donanemab)
Situations where amyloid PET or lumbar puncture is not accessible, not desired, or has already been deferred

The test is not currently recommended as routine screening in cognitively normal individuals without symptoms. Its performance in the general asymptomatic population is less well established.

WHEN TO FOLLOW UP

Discuss your p-tau217 result with a clinician if:

Your result is in the positive range — confirmatory amyloid PET or CSF testing may be recommended
Your result is indeterminate — repeat testing or additional biomarkers may be ordered
Your result is negative but symptoms are progressing — other causes of cognitive change need evaluation
You are considering or already on Alzheimer's disease-modifying therapy

BOTTOM LINE

Bottom line: P-tau217 is a blood plasma biomarker that identifies Alzheimer's-related brain changes. A positive result (above the assay-specific cutoff) increases the likelihood of AD pathology; a negative result makes it less likely. Cutoffs differ significantly between platforms — Lumipulse, ALZpath, AD-Detect, and PrecivityAD2 are not interchangeable. An indeterminate (gray zone) result is common and prompts further evaluation rather than a definitive conclusion. P-tau217 is an aid to diagnosis, not a diagnosis itself.

FAQ about p-tau217

Can p-tau217 go back to normal?

This is an active area of research. Early data from Alzheimer's disease-modifying treatment trials (lecanemab, donanemab) suggest that successful amyloid removal is associated with reductions in p-tau217 levels, though the magnitude of change and its clinical meaning are still being characterized. A single p-tau217 result should not be interpreted in isolation — trends over time and treatment context matter. Whether a decline in p-tau217 on treatment translates to meaningful cognitive benefit remains under active investigation. Do not interpret a declining p-tau217 value as confirmation that a treatment is working without clinical guidance.
What is a normal p-tau217 range?

Reference ranges are assay-specific and not interchangeable between platforms. On the most widely used clinical platform (Lumipulse/Fujirebio), published validation studies and clinical use at Mayo Clinic classify results as: negative (≤ ~0.18–0.20 pg/mL), indeterminate (~0.18–0.32 pg/mL), or positive (≥ ~0.32–0.33 pg/mL). Always use the reference range printed on your own lab report, which will show the cutoffs for the specific assay used.
What does a high p-tau217 mean?

A high p-tau217 (above the positive cutoff on your report) indicates that Alzheimer's-type amyloid and tau pathology is likely present in the brain. It supports a diagnosis of Alzheimer's disease when combined with clinical symptoms and cognitive testing, but does not confirm it alone. Your clinician may recommend amyloid PET imaging or CSF biomarkers for confirmation if the result would change your treatment plan.
What does it mean if my p-tau217 is in the gray zone?

A gray zone or indeterminate p-tau217 result falls between the negative and positive cutoffs. Roughly 15–30% of tested patients fall in this range. It reflects genuine uncertainty and typically prompts further evaluation — either repeat testing after symptom progression, additional biomarkers (Aβ42, NfL), or amyloid PET imaging. An indeterminate result is not a "positive" result.
Is the p-tau217 test the same as an Alzheimer's diagnosis?

No. P-tau217 is a diagnostic aid, not a diagnosis. A positive result increases the likelihood that Alzheimer's-related brain changes are present, but diagnosis requires integration of the result with clinical symptoms, cognitive testing, history, and often confirmatory testing. A negative result makes Alzheimer's less likely but does not completely exclude it.
What is the difference between p-tau217 and p-tau181?

Both are phosphorylated forms of the tau protein used as Alzheimer's biomarkers, but p-tau217 generally shows higher diagnostic accuracy in published studies. P-tau217 rises earlier and more steeply in Alzheimer's disease and correlates more strongly with amyloid PET results. Many specialty clinics now prefer p-tau217 when it is available.
Do I still need a PET scan or lumbar puncture after a p-tau217 result?

Sometimes. P-tau217 can rule in or rule out Alzheimer's-type pathology for most patients with confidence, potentially avoiding PET or lumbar puncture. However, confirmatory testing may still be recommended when results are borderline (gray zone), when the clinical picture is atypical, or when confirmation would directly change treatment decisions — particularly for Alzheimer's disease-modifying therapies that require confirmed amyloid pathology.
Why does my number look different from ranges I find online?

Different assay platforms produce different absolute numbers for the same patient. Lumipulse reports in pg/mL (typically 0.05–0.50+ range); AD-Detect (C2N) reports as a percentage (%p-tau217) in a different numeric range; ALZpath Simoa uses yet another scale. Never apply cutoffs from one platform to results from another. The reference range on your own report is the only valid interpretation guide.
What if my p-tau217 is intermediate but my amyloid PET scan is positive?

An intermediate p-tau217 result does not rule out Alzheimer's-related pathology. Blood biomarkers are screening and triage tools, while amyloid PET imaging directly measures amyloid deposition in the brain. A positive amyloid PET scan generally carries greater diagnostic weight than an intermediate blood biomarker result. It is possible to have an intermediate p-tau217 result while already demonstrating amyloid pathology on PET imaging, particularly in early disease stages.
Can kidney disease affect p-tau217 results?

Reduced kidney function may increase circulating p-tau217 levels and should be considered when interpreting results. Clinicians generally evaluate p-tau217 alongside kidney function markers such as creatinine, cystatin C, and eGFR.

Lab Results Explained and Tracked

All Your Lab Results.
One Simple Dashboard.

What does it mean if your p-tau217 result is too high?

High p-tau217 means Alzheimer's-related amyloid and tau pathology is likely present in the brain. The result supports — but does not confirm — Alzheimer's disease, and must be interpreted alongside cognitive testing, symptoms, and clinical history. Your clinician may recommend confirmatory amyloid PET imaging or CSF biomarkers. A positive p-tau217 may also support eligibility for disease-modifying treatments such as lecanemab or donanemab, which require confirmed amyloid pathology.

Related Health Conditions

All Your Lab Results.
One Simple Dashboard.

Import, Track, and Share Your Lab Results Easily

Import, Track, and Share Your Lab Results

Import lab results from multiple providers, track changes over time, customize your reference ranges, and get clear explanations for each result. Everything is stored securely, exportable in one organized file, and shareable with your doctor—or anyone you choose.

Cancel or upgrade anytime

What does it mean if your p-tau217 result is too low?

Low p-tau217 makes Alzheimer's-type amyloid and tau pathology unlikely at the time of testing. This is a reassuring result in a patient being evaluated for possible Alzheimer's disease, and may help redirect evaluation toward other potential causes of cognitive symptoms. A negative result does not completely exclude early Alzheimer's disease and should always be interpreted alongside clinical assessment.

Related Biomarkers

Article Review & Sources

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We're committed to accuracy and transparency — see our editorial policy for details.

Laboratories

Bring All Your Lab Results Together — In One Place

We accept reports from any lab, so you can easily collect and organize all your health information in one secure spot.

Pricing Table

Gather Your Lab History — and Finally Make Sense of It

Finally, Your Lab Results Organized and Clear

Choose the plan that fits you — and turn scattered lab reports into clear insights you can finally use.

Pick a plan that fits you — and turn scattered lab reports into clarity.

Personal plans

Professional plan

$79/ year

Advanced Plan

Access your lab reports, explanations, and tracking tools.

Import lab results from any provider
Track all results with visual tools
Customize your reference ranges
Export your full lab history anytime
Share results securely with anyone
Receive 5 reports entered for you
Cancel or upgrade anytime

$250/ once

Unlimited Account

Pay once, access everything—no monthly fees, no limits.

Import lab results from any provider
Track all results with visual tools
Customize your reference ranges
Export your full lab history anytime
Share results securely with anyone
Receive 10 reports entered for you
No subscriptions. No extra fees.

Professional plan

$45/ month

Pro Monthly

Designed for professionals managing their clients' lab reports

Import lab results from any provider
Track lab results for multiple clients
Customize reference ranges per client
Export lab histories and reports
Share results and reports with clients
Invite clients to their accounts
Begin with first report entered by us
Cancel or upgrade anytime

About membership

What's included in a Healthmatters membership

Import Lab Results from Any Source

Easily upload lab results from any provider, whether it's a hospital, independent lab, or home testing service. We support PDFs, scanned documents, and JPEGs from patient portals. No need to log in to multiple platforms — everything is centralized in one secure space.

Easily upload lab results from any provider — we support PDFs, scans, and images. Keep all your reports organized in one secure place.

See Your Health Timeline

Every lab result is automatically organized on a chronological timeline, giving you a complete picture of your health journey. Whether you're tracking a condition, managing treatments, or staying proactive, the timeline helps you and your doctor understand how things progress over time.

Every lab result is automatically organized on a chronological timeline, giving you a complete picture of your health journey.

Understand What Your Results Mean

Whether it's a blood test, GI panel, urinalysis, or something else, lab reports measure numerous biomarkers that reveal what's happening inside your body. Our extensive database covers over 10,000 biomarkers, providing clear, simple explanations of what each result means and how you can take action—no matter your membership level. Say goodbye to confusion and get the insights you need to better understand your health.

Our database covers over 10,000 biomarkers with clear, simple explanations—so you can finally understand your results and what to do next.

Enter Your Lab Reports Yourself — Always Free Enter Your Lab Reports — Always Free

If you'd like to handle inputting your health data into your account, you can do so with our easy-to-use data entry forms. Our user-friendly form is designed to guide you through the quick and easy submission process, making it simple to keep track of your health metrics. This is available to both Advanced plan and Unlimited plan members.

Our user-friendly form guides you through a quick, simple submission process, making it easy to enter your health metrics.

Add your results anytime with our easy entry form. It's quick, guided, and helps you stay organized — free for all members.

Visualize Your Results

View your lab data through easy-to-read graphs and tables. Quickly spot patterns, track changes, and compare results across different dates — all without digging through multiple reports. You can also select and compare graphs of specific biomarkers side-by-side to better understand how they relate and change over time.

See your lab reports in clear graphs and tables. Spot patterns, track changes, and compare results over time — all in one place.

Export Your Complete Lab History in a Single File Export Your Complete Lab History

After collecting lab results from different providers, you can download your entire history combined into a single file. Choose from PDF, Excel, or CSV formats to easily review, share, or get a second opinion—no more juggling multiple reports.

After collecting lab results from different providers, you can download your entire history combined into a single file.

Comprehensive Data Entry Service for Your Reports Data Entry Service for Your Reports

Our inclusive service handles the data entry for your lab reports. Just submit your information and we'll take care of the rest. Advanced plan members receive five reports entered for free, then $15 per report after that. Unlimited plan members receive ten report entries for free, then $15 per report after that.

Our inclusive service handles the data entry for your lab reports. Just submit your information and we'll take care of the rest.

Securely Share With Anyone You Trust

Whether you're working with a doctor, nutritionist, caregiver, or wellness coach, you can securely share your complete lab history by sending an invite link to anyone you trust. You have full control over who sees your information and for how long, ensuring your privacy and peace of mind at every step.

Share your full lab history with your doctor, nutritionist, or coach using a secure invite link.

Discover

Let Your Lab Results Tell the Full Story

Once your results are in one place, see the bigger picture — track trends over time, compare data side by side, export your full history, and share securely with anyone you trust.

Bring all your results together to compare, track progress, export your history, and share securely.

I have been using Healthmatters.io since 2021. I travel all over the world and use different doctors and health facilities. This site has allowed me to consolidate all my various test results over 14 years in one place. And every doctor that I show this to has been impressed. Because with any health professional I talk to, I can pull up historical results in seconds. It is invaluable. Even going back to the same doctor, they usually do not have the historical results from their facility in a graph format. That has been very helpful.

Anthony

Unlimited Plan Member since 2021

What fantastic service and great, easy-to-follow layouts! I love your website; it makes it so helpful to see patterns in my health data. It's truly a pleasure to use. I only wish the NHS was as organized and quick as Healthmatters.io. You've set a new standard for health tracking!

Karin

Advanced Plan Member since 2020

As a PRO member and medical practitioner, Healthmatters.io has been an invaluable tool for tracking my clients' data. The layout is intuitive, making it easy to monitor trends and spot patterns over time. The ability to customize reports and charts helps me present information clearly to my clients, improving communication and outcomes. It's streamlined my workflow, saving me time and providing insights at a glance. Highly recommended for any practitioner looking for a comprehensive and user-friendly solution to track patient labs!

Paul

Healthmatters Pro Member since 2024

We implement proven measures to keep your data safe.

At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.

P-tau217 Blood Test: Normal Range, Results Explained, and What High Levels Mean

QUICK ANSWER

WHAT IS P-TAU217?

WHAT DOES A HIGH P-TAU217 MEAN?

WHAT DOES A LOW P-TAU217 MEAN?

WHAT DOES AN INDETERMINATE / GRAY ZONE RESULT MEAN?

WHY DO REFERENCE RANGES DIFFER BY ASSAY?

P-TAU217 AND THE P-TAU217/Aβ42 RATIO

CAN P-TAU217 BE ELEVATED BEFORE SYMPTOMS APPEAR?

WHEN IS THE P-TAU217 TEST ORDERED?

WHEN TO FOLLOW UP

BOTTOM LINE

FAQ about p-tau217

Can p-tau217 go back to normal?

What is a normal p-tau217 range?

What does a high p-tau217 mean?

What does it mean if my p-tau217 is in the gray zone?

Is the p-tau217 test the same as an Alzheimer's diagnosis?

What is the difference between p-tau217 and p-tau181?

Do I still need a PET scan or lumbar puncture after a p-tau217 result?

Why does my number look different from ranges I find online?

What if my p-tau217 is intermediate but my amyloid PET scan is positive?

Can kidney disease affect p-tau217 results?

All Your Lab Results. One Simple Dashboard.

What does it mean if your p-tau217 result is too high?

Related Health Conditions

All Your Lab Results. One Simple Dashboard.

Import, Track, and Share Your Lab Results Easily

Import, Track, and Share Your Lab Results

What does it mean if your p-tau217 result is too low?

Related Biomarkers

Article Review & Sources

Bring All Your Lab Results Together — In One Place

Gather Your Lab History — and Finally Make Sense of It

Finally, Your Lab Results Organized and Clear

Advanced Plan

Unlimited Account

Pro Monthly

What's included in a Healthmatters membership

Import Lab Results from Any Source

See Your Health Timeline

Understand What Your Results Mean

Enter Your Lab Reports Yourself — Always Free Enter Your Lab Reports — Always Free

Visualize Your Results

Export Your Complete Lab History in a Single File Export Your Complete Lab History

Comprehensive Data Entry Service for Your Reports Data Entry Service for Your Reports

Securely Share With Anyone You Trust

Let Your Lab Results Tell the Full Story

Once your results are in one place, see the bigger picture — track trends over time, compare data side by side, export your full history, and share securely with anyone you trust.

Bring all your results together to compare, track progress, export your history, and share securely.

What Healthmatters Members Are Saying

Use promo code to save 10% off any plan.

We implement proven measures to keep your data safe.

All Your Lab Results.
One Simple Dashboard.

All Your Lab Results.
One Simple Dashboard.